Index

VOLUME 12, 1999

Author Index

Abati A, 206
Andreoli V, 206
Ascari S, 82

Barker WW, 72
Bassett SS, 200
Bereczki D, 194
Bowen JD, 53
Bremner JD, 95
Brown GG, 180
Brown SJ, 180
Buchalter E, 7
Burns A, 21

Carbognin G, 206
Chemerinski E, 128
Costa P, 1
Csiba L, 194

Dew MA, 67
DiPaola R, 49
Donaldson C, 21
Doraiswamy PM, 39
Duara R, 72

Evans JD, 11

Fekete I, 194
Ferrari R, 82
Ferris SH, 168
Fladby T, 16
Fleg J, 1
Frederick BdB, 107

Gesztelyi R, 194
Giambanco V, 7
Gibbons LE, 53
Golomb J, 168
Gorell JM, 180
Gray S, 1
Green TD, 67
Grønli O, 16

Harwood DG, 72
Heaton RK, 11
Herbst J, 1
Holschneider DP, 150
Houck PR, 67

Jeste DV, 11
Jones DE, 76
Jorge R, 128
Juby A, 87

Kawabata K, 189
Kawas C, 1
Kaye JA, 76
Kellermann M, 194
Kishiyama SS, 76
Kluger A, 168
Kukull WA, 53
Kumar A, 93, 95
Kupfer DJ, 67

Lantz MS, 7
Larson EB, 53
Leuchter AF, 150
Logsdon RG, 53
Løseth S, 16

Mack JL, 211
Mazumdar S, 67
McCormick WC, 53
McCurry SM, 53
McDonald C, 180
McLendon BM, 39
Meltzer CC, 137
Menza MA, 49
Miller MD, 67
Mittelman MS, 168
Moore CM, 107
Mulsant BH, 67
Mussi C, 82

Narayan M, 95
Negron AE, 11
Nobler MS, 118

Oken BS, 76
Okuda B, 189
Ownby RL, 72

Palermo B, 49
Palmer BW, 11
Patterson MB, 211
Paulsen JS, 11
Pelton GH, 118

Index

VOLUME 12, 1999

Author Index

Abati A, 206
Andreoli V, 206
Ascari S, 82

Barker WW, 72
Bassett SS, 200
Bereczki D, 194
Bowen JD, 53
Bremner JD, 95
Brown GG, 180
Brown SJ, 180
Buchalter E, 7
Burns A, 21

Carbognin G, 206
Chemerinski E, 128
Costa P, 1
Csiba L, 194

Dew MA, 67
DiPaola R, 49
Donaldson C, 21
Doraiswamy PM, 39
Duara R, 72

Evans JD, 11

Fekete I, 194
Ferrari R, 82
Ferris SH, 168
Fladby T, 16
Fleg J, 1
Frederick BdB, 107

Gesztelyi R, 194
Giambanco V, 7
Gibbons LE, 53
Golomb J, 168
Gorell JM, 180
Gray S, 1
Green TD, 67
Grønli O, 16

Harwood DG, 72
Heaton RK, 11
Herbst J, 1
Holschneider DP, 150
Houck PR, 67

Jeste DV, 11
Jones DE, 76
Jorge R, 128
Juby A, 87

Kawabata K, 189
Kawas C, 1
Kaye JA, 76
Kellermann M, 194
Kishiyama SS, 76
Kluger A, 168
Kukull WA, 53
Kumar A, 93, 95
Kupfer DJ, 67

Lantz MS, 7
Larson EB, 53
Leuchter AF, 150
Logsdon RG, 53
Løseth S, 16

Mack JL, 211
Mazumdar S, 67
McCormick WC, 53
McCurry SM, 53
McDonald C, 180
McLendon BM, 39
Meltzer CC, 137
Menza MA, 49
Miller MD, 67
Mittelman MS, 168
Moore CM, 107
Mulsant BH, 67
Mussi C, 82

Narayan M, 95
Negron AE, 11
Nobler MS, 118

Oken BS, 76
Okuda B, 189
Ownby RL, 72

Palermo B, 49
Palmer BW, 11
Patterson MB, 211
Paulsen JS, 11
Pelton GH, 118

Pollock BG, 67

Rahill AA, 180
Reisberg B, 168
Renshaw PF, 107
Reynolds CF III, 67
Ricketts MH, 49
Robinson RG, 128

Sackeim HA, 118
Sacktor N, 1
Sage JI, 49
Salvioli G, 82
Schuster M, 16
Sexton H, 16
Shults C, 180
Sillanpaa M, 180
Sjøholm H, 16
Sugita M, 189

Tachibana H, 189
Takeda M, 189
Tariot PN, 211
Teri L, 53
Trabucchi M, 29
Tueth MJ, 60

Vantini G, 206

Zuberi P, 60

Subject Index

Abnormal Involuntary Movement Scale, 11–15
Abuse, 63
Acetylcholine, 143
Activities of Daily Living, 29–37
Age, 76–80, 110, 119, 140–145, 152–153, 195, 197
Aggression, 63, 211–221, 223
Agitation, 63
Alcohol, 65
Alzheimer's disease, 21–47, 53–58, 72–74, 118–125, 144, 168–178, 200–204, 211–223
Alzheimer's Disease Assessment Scale, 39–47
Anticholinergics, 82–86
Antidepressants, 7–9, 67–70, 207–209
Antipsychotics, 64
Anxiety, 49–52
Assault, 62–63

Basal ganglia, 100
Beck Depression Inventory, 194–198
Behavioral changes, 63–65, 211–221, 223
Behavior Rating Scale for Dementia, 211–221, 223
Benzodiazepines, 82–86
Bereavement-related depression, 68–69
Biochemistry, 107–114
Blood flow, 118–125, 189–192
Blood pressure, 1–5
Brain, 16–19, 93–104, 107–114, 137–145, 189–192

Caregiver, 21–27
Cerebral blood flow, 118–125, 189–192
Cerebrospinal fluid, 98
Clinical Global Impression scale, 206–209
Clinician's Interview Based Impression of Change, 39–47
Clock drawing, 87–90
Cognitive function, 11–15, 168–178, 180–187
Competency, 200–204
Computed tomography, 93–94, 122–124
Confusion, 61, 82–86
Confusion Assessment Method, 82–86
Corticobasal degeneration, 189–192
Criterion Neuropsychology Battery, 180–187
Cued Selective Reminding test, 1–5

Delirium, 82–86, 157–159
Dementia, 11–15, 21–27, 110–113, 118–125, 153–156, 168–187, 211–223
Dementia Rating Scale, 11–15, 180–187
Depression, 11–15, 49–52, 67–74, 95–104, 113–114, 118–125, 128–134, 143–144, 156–157, 194–198, 206–223
Deterioration scale, 168–178
Donepezil, 36, 39–47
Dopamine, 140–141

Electroconvulsive therapy, 114
Electroencephalography, 150–160
Emergencies, 60–65
Epilepsy, 159–160

Frontal lobe, 98

Ganglia, 100
Genetics, 49–52
Global Deterioration Scale, 168–178

Hamilton Depression and Anxiety Scales, 49–52
Hamilton Rating Scale for Depression, 11–15, 67–70, 206–209

High-intensity lesions, 100–101
Homicidality, 62–63
Hopkins Competency Assessment Test, 201–203
Huntington's disease, 133–134
Hypercin, 7–9
Hypertension, 1–5

Inertia, 211–221, 223
Involuntary movement, 11–15
Irritability, 211–221, 223

Kinetic modeling, 139

Late-life depression, 95–104, 118–125
Late-life mental disorders, 95–104, 143–144
Lesions, 100–101
Life-threatening syndromal presentations, 64–65

Magnetic resonance imaging, 93–105, 139–140
Magnetic resonance spectroscopy, 107–114
Manchester Carer's Project, 21–27
Mattis Dementia Rating Scale, 11–15
Memory, 1–5
Mental disorders, 95–104, 143–144
Metabolism, 118–125, 138
Mini–Mental State Examination, 29–37, 87–90, 180–187, 212–221, 223
Motor disorders, 145

Neglect, 63
Neuroanatomic substrates, 95–104
Neurochemical imaging, 131–132
Neuroimaging, 93–94, 101–104
Neuroleptics, 82–86
Neuropharmacology, 137–145
Neurophysiology, 150–160
Neuropsychology, 168–178, 180–187, 200–204
Neuroreceptors, 143–144
Neurotransmitters, 138, 140–145
Nortriptyline, 67–70

Organic brain disease, 16–19

Parkinson's disease, 49–52, 132–133, 145, 180–187
Paroxetine, 67–70
Physical assault, 62–63
Positive and Negative Syndrome Scale, 11–15
Positron emission tomography, 93–94, 124, 137–145
Poststroke depression, 131–132, 134, 194–198
Psychiatric emergencies, 60–65
Psychiatric illness, 93–114
Psychopathology, 11–15
Psychosis, 95–104, 211–221, 223
Psychotropic medications, 64

Quantitative electroencephalography, 150–160

Reality Orientation Therapy, 33
Reboxetine, 206–209
Receptor studies, 137–145
Regional cerebral blood flow, 189–192

St. John's wort, 7–9
Schizophrenia, 11–15
Serotonin, 49–52, 141–142
Serum anticholinergic activity, 82–86
Simpson-Angus Extrapyramidal Symptom Scale, 11–15
Single-photon emission computed tomography, 93–94, 122–124
Sleep, 53–58, 67–70
Spectroscopy, 93–94, 107–114
Stroke, 129–132, 194–198
Substance-induced behavioral changes, 63–65
Suicidality, 61–62
Systolic blood pressure, 1–5

Tacrine, 35–36
Temporal lobe, 98–100
Total sleep deprivation, 67–70
Tracer kinetic modeling, 139
Tricyclic antidepressants, 207–209

Vegetative symptoms, 211–221, 223
Ventricular volume, 98
Vision, 76–80
Volumetric measures, 96–101